fig5

Figure 5. Clinicopathological and biological characteristics of TCGA prostate cancer patients according to the FRG recurrence index risk group. (A-E) Associations between the FRG recurrence index risk score and clinicopathological features, including pathological T stage (A), pathological N stage (B), PSA level (C), overall stage (D), and tumor grade (E). (F and G) Positive correlations between drug sensitivity to Abiraterone (F) or Enzalutamide (G) and the FRG recurrence index risk score in prostate cancer patients. (H) The top five enriched terms in the Biological Process (BP), Cellular Component (CC), and Molecular Function (MF) categories from Gene Ontology (GO) analysis. (I) The top 10 enriched terms from the KEGG pathway analysis. GO and KEGG enrichment analyses were performed by comparing the high- and low-risk groups of TCGA prostate cancer patients. *P < 0.05, ***P < 0.001, ****P < 0.0001. The term “risk score” refers to scores calculated from our FRGs-based model.